Mark A. Socinski

Q: What Schools Are Affiliated With Mark A. Socinski

Mark A. Socinski is affiliated with the following schools: McGill University, University of Alberta, Stanford University, University of Chicago, University of Las Palmas de Gran Canaria, University of Pittsburgh, University of North Carolina at Chapel Hill, University of Turin, Duke University, University of Utah, University of Western Australia, University of Pennsylvania

Mark A. Socinski's AcademicInfluence.com Rankings

Mark A. Socinski

Philosophy

#6027

World Rank

#8987

Historical Rank

Logic

#3222

World Rank

#4347

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Mark A. Socinski's Degrees

Doctorate Medicine University of Pittsburgh
Bachelors Biology University of Notre Dame

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2026

Why Is Mark A. Socinski Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Mark A. Socinski's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC (2018) (2238)
Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. (2014) (1364)
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial (2008) (1275)
First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer (2017) (1217)
Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. (1988) (640)
GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR EXPANDS THE CIRCULATING HAEMOPOIETIC PROGENITOR CELL COMPARTMENT IN MAN (1988) (582)
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. (2019) (560)
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. (2012) (537)
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. (2010) (497)
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. (2016) (491)
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. (2015) (402)
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. (2014) (400)
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. (2002) (376)
Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. (2004) (360)
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. (2013) (324)
Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer. (2008) (323)
Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. (2016) (297)
Cardiac Toxicity After Radiotherapy for Stage III Non-Small-Cell Lung Cancer: Pooled Analysis of Dose-Escalation Trials Delivering 70 to 90 Gy. (2017) (275)
Gene expression profiling reveals reproducible human lung adenocarcinoma subtypes in multiple independent patient cohorts. (2006) (267)
Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). (2014) (266)
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? (2010) (256)
Lung Squamous Cell Carcinoma mRNA Expression Subtypes Are Reproducible, Clinically Important, and Correspond to Normal Cell Types (2010) (248)
Measuring the side effects of taxane therapy in oncology (2003) (247)
Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. (2009) (245)
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. (2014) (239)
A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically Defined Advanced Non–Small Cell Lung Cancer (2013) (232)
Chemotherapeutic management of stage IV non-small cell lung cancer. (2003) (213)
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous Non-Small-Cell Lung Cancer (IMpower131): Results From a Randomized Phase III Trial. (2020) (213)
IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC. (2018) (212)
Differential Pathogenesis of Lung Adenocarcinoma Subtypes Involving Sequence Mutations, Copy Number, Chromosomal Instability, and Methylation (2012) (209)
High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. (2002) (205)
Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. (2013) (194)
Reinforcement Learning Strategies for Clinical Trials in Nonsmall Cell Lung Cancer (2011) (187)
Treatment of non-small cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd edition). (2007) (176)
Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer (2008) (175)
Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. (2008) (171)
Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial. (2004) (159)
Dose‐escalating conformal thoracic radiation therapy with induction and concurrent carboplatin/paclitaxel in unresectable stage IIIA/B nonsmall cell lung carcinoma (2001) (159)
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. (2009) (155)
Current treatments for advanced stage non-small cell lung cancer. (2009) (154)
Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. (2016) (153)
Granulocyte-macrophage colony-stimulating factor induces the expression of the CD11b surface adhesion molecule on human granulocytes in vivo. (1988) (143)
Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. (2005) (142)
The impact of age on toxicity, response rate, quality of life, and survival in patients with advanced, Stage IIIB or IV nonsmall cell lung carcinoma treated with carboplatin and paclitaxel (2003) (141)
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. (2012) (136)
Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer (2009) (135)
Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial. (2020) (134)
NSCLC, metastaticCheckMate 026: A phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage iv/recurrent programmed death ligand 1 (PD-L1)−positive NSCLC (2016) (130)
Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy. (2007) (129)
Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation–positive non-small cell lung cancer (NSCLC) patients. (2013) (128)
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study. (2015) (120)
Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer (2008) (118)
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer (2018) (116)
Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. (2011) (113)
IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer. (2021) (111)
Considerations for second-line therapy of non-small cell lung cancer. (2008) (107)
Efficacy and safety of crizotinib in patients (pts) with advanced MET exon 14-altered non-small cell lung cancer (NSCLC). (2016) (106)
Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer (NSCLC): Preliminary results of a multicenter phase II trial. (2006) (104)
Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. (2017) (102)
Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis (2007) (101)
Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring BRAF mutations in the Lung Cancer Mutation Consortium (2015) (101)
The Clinical Viewpoint: Definitions, Limitations of RECIST, Practical Considerations of Measurement (2013) (97)
Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer? (2005) (94)
Women and lung cancer: epidemiology, tumor biology, and emerging trends in clinical research. (2007) (91)
Gefitinib (IRESSA) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label Phase III study (INTEREST): PRS-02 (2007) (91)
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. (2017) (89)
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials (2017) (88)
Abstract CT082: Impact of tumor mutation burden on the efficacy of first-line nivolumab in stage iv or recurrent non-small cell lung cancer: An exploratory analysis of CheckMate 026 (2017) (87)
Limited-stage small-cell lung cancer: the current status of combined-modality therapy. (2007) (82)
Induction Chemotherapy with Carboplatin, Irinotecan, and Paclitaxel Followed by High Dose Three-Dimension Conformal Thoracic Radiotherapy (74 Gy) with Concurrent Carboplatin, Paclitaxel, and Gefitinib in Unresectable Stage IIIA and Stage IIIB Non-small Cell Lung Cancer (2008) (81)
Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer. (2017) (81)
Clinicopathologic Features of Advanced Squamous NSCLC. (2016) (80)
Seeking a home for a PET, part 2: Defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer. (2004) (80)
Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial. (2012) (79)
Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. (2013) (78)
Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer. (2006) (77)
Overall survival (OS) analysis of IMpower150, a randomized Ph 3 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous (NSQ) NSCLC. (2018) (76)
Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors (2007) (76)
Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. (2015) (73)
Tecemotide ( L-BLP 25 ) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer ( START ) : a randomised , double-blind , phase 3 trial (2013) (73)
Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and Treatment Selection Based on Two Large Randomized Clinical Trials (2009) (72)
Seeking a home for a PET, part 1: Defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses. (2004) (70)
Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. (2004) (70)
Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. (2005) (69)
A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer (2010) (69)
An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC). (2011) (69)
Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib. (2009) (68)
Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV (2009) (68)
Single-agent paclitaxel in the treatment of advanced non-small cell lung cancer. (1999) (68)
Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer (2016) (67)
Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406. (2010) (67)
Rationale for Chemotherapy, Immunotherapy, and Checkpoint Blockade in SCLC: Beyond Traditional Treatment Approaches (2013) (66)
Evidence-based medicine in the treatment of non-small-cell lung cancer. (2000) (64)
Cytotoxic Chemotherapy in Advanced Non-Small Cell Lung Cancer (2004) (63)
A randomized, phase III multicenter trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in patients with advanced or metastatic non-small-cell lung cancer. (2010) (62)
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain. (2021) (62)
Beliefs among pulmonologists and thoracic surgeons in the therapeutic approach to non-small cell lung cancer. (2000) (61)
Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients. (2020) (61)
Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets. (2013) (60)
Randomized phase II trial of docetaxel/irinotecan and gemcitabine/irinotecan with or without celecoxib in the second-line treatment of non-small-cell lung cancer. (2006) (60)
A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) non-small cell lung cancer (NSCLC): Update of the Alpha Oncology trial (A1–99002L) (2005) (59)
Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC). (2011) (59)
START: A phase III study of L-BLP25 cancer immunotherapy for unresectable stage III non-small cell lung cancer. (2013) (59)
Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. (2015) (58)
Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Who Previously Progressed on Erlotinib (2015) (57)
Treatment Paradigms for Advanced Stage Non-small Cell Lung Cancer in the Era of Multiple Lines of Therapy (2009) (56)
Bronchogenic Cancer, Metastases, and Aging (1983) (56)
Phase II study of BBR 3464 as treatment in patients with sensitive or refractory small cell lung cancer (2006) (54)
A Retrospective Analysis of VeriStrat Status on Outcome of a Randomized Phase II Trial of First-Line Therapy with Gemcitabine, Erlotinib, or the Combination in Elderly Patients (Age 70 Years or Older) with Stage IIIB/IV Non–Small-Cell Lung Cancer (2013) (54)
Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. (2017) (53)
PIONEER: a phase III randomized trial of paclitaxel poliglumex versus paclitaxel in chemotherapy-naive women with advanced-stage non-small-cell lung cancer and performance status of 2. (2006) (53)
Second‐line, low‐dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first‐line chemotherapy with carboplatin plus paclitaxel (2002) (53)
Phase 1/2 Study of the CD56‐Targeting Antibody‐Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small‐Cell Lung Cancer Patients With Extensive‐Stage Disease (2017) (53)
KRAS mutant lung cancer: progress thus far on an elusive therapeutic target (2015) (51)
Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: report of a phase II trial. (1999) (51)
CALGB 30704 (Alliance): A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2014) (51)
A retrospective analysis of outcomes by age in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel vs. paclitaxel plus carboplatin for advanced non-small cell lung cancer. (2011) (50)
Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC). (2018) (50)
Successful treatment of disseminated Fusarium infection after autologous bone marrow transplantation for acute myeloid leukemia. (1991) (50)
The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma (2013) (50)
Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer (2010) (50)
HSP90 inhibitors in lung cancer: promise still unfulfilled. (2016) (50)
Incremental Innovation and Progress in Advanced Squamous Cell Lung Cancer: Current Status and Future Impact of Treatment (2016) (50)
A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC). (2013) (48)
A randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin (GC) chemotherapy plus necitumumab (IMC-11F8/LY3012211) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). (2014) (48)
Clinical considerations for the development of biosimilars in oncology (2015) (47)
Crizotinib in Patients With MET-Amplified NSCLC. (2021) (47)
The Role of Anti-angiogenesis in Non-small-cell Lung Cancer: an Update (2015) (46)
Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations (2019) (46)
Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B. (2006) (46)
Results of a Single Institution Experience with Dose-Escalated Chemoradiation for Locally Advanced Unresectable Non-Small Cell Lung Cancer (2017) (44)
Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non–Small Cell Lung Cancer (2015) (44)
Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC) (2019) (44)
Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials (2017) (44)
Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study. (2017) (44)
Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy. (2006) (43)
Duration of first-line chemotherapy in advanced non small-cell lung cancer: less is more in the era of effective subsequent therapies. (2007) (43)
A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. (2006) (43)
Molecular and clinical subgroup analyses from a phase III trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (INTEREST) (2008) (43)
Management of Non-Small Cell Lung Cancer with Oligometastasis (2012) (42)
Enhancement of superoxide anion release by granulocytes harvested from patients receiving granulocyte‐macrophage colony‐stimulating factor (1989) (42)
Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. (2013) (41)
Late Complications of High-Dose (≥66 Gy) Thoracic Conformal Radiation Therapy in Combined Modality Trials in Unresectable Stage III Non-small Cell Lung Cancer (2009) (41)
Antibodies to the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer: Current Status of Matuzumab and Panitumumab (2007) (41)
Safety and Efficacy of Combining Sunitinib with Bevacizumab + Paclitaxel/Carboplatin in Non-small Cell Lung Cancer (2010) (41)
Neoadjuvant Treatment of Stage IIIA Non‐Small Cell Lung Cancer Long‐Term Results (1994) (41)
A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC). (2009) (40)
Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results. (2018) (39)
Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance? (2008) (39)
LBA1_PRPrimary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150) (2017) (39)
[Breast cancer in the early stage]. (2012) (39)
Acceptable safety of bevacizumab therapy in patients with brain metastases due to non-small cell lung cancer (2008) (39)
Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials. (2012) (38)
Long-Term Follow-Up of a Phase I/II Trial of Dose Escalating Three-Dimensional Conformal Thoracic Radiation Therapy with Induction and Concurrent Carboplatin and Paclitaxel in Unresectable Stage IIIA/B Non-small Cell Lung Cancer (2008) (38)
LBA39_PRNERATINIB (N) WITH OR WITHOUT TEMSIROLIMUS (TEM) IN PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING HER2 SOMATIC MUTATIONS: AN INTERNATIONAL RANDOMIZED PHASE II STUDY (2014) (37)
Efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC): Results from a phase II study (2007) (37)
Lung cancer presenting with a solitary colon metastasis detected on positron emission tomography scan. (2006) (36)
Poziotinib in Non–Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial (2021) (36)
Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer (2010) (36)
Prevention of Delayed Chemotherapy-Induced Nausea and Vomiting After Moderately High to Highly Emetogenic Chemotherapy: Comparison of Ondansetron, Prochlorperazine, and Dexamethasone (2005) (36)
IIB or not IIB: the current question in staging non-small cell lung cancer. (1997) (36)
A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age ≥70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer (2011) (36)
Carboplatin/Paclitaxel or Carboplatin/Vinorelbine Followed by Accelerated Hyperfractionated Conformal Radiation Therapy: Report of a Prospective Phase I Dose Escalation Trial From the Carolina Conformal Therapy Consortium (2004) (35)
Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression. (2017) (35)
MA04.02 Neratinib ± Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study (2017) (35)
MET Exon 14 Skipping Mutations in Non–Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations (2021) (35)
Stage II nonseminomatous germ cell tumors of the testis: an analysis of treatment options in patients with low volume retroperitoneal disease. (1988) (34)
Current approaches to advanced-stage non-small-cell lung cancer: first-line therapy in patients with a good functional status. (2006) (34)
Multitargeted receptor tyrosine kinase inhibition: an antiangiogenic strategy in non-small cell lung cancer. (2011) (34)
Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing (2001) (34)
Maintenance therapy in advanced non-small cell lung cancer: current status and future implications. (2011) (34)
Seeking a home for a PET, part 3: Emerging applications of positron emission tomography imaging in the management of patients with lung cancer. (2004) (34)
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial (2022) (34)
Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non–small cell lung cancer (2017) (33)
Estrogen‐receptor‐related protein p29 in primary nonsmall cell lung carcinoma (1998) (33)
Management of normal tissue toxicity associated with chemoradiation (primary skin, esophagus, and lung). (2013) (33)
Concurrent Chemoradiotherapy for Unresectable Stage III Non–Small Cell Lung Cancer (2005) (33)
Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer (2015) (33)
Outcomes Associated with Brain Metastases in a Three-Arm Phase III Trial of Gemcitabine-Containing Regimens Versus Paclitaxel Plus Carboplatin for Advanced Non-small Cell Lung Cancer (2010) (33)
Diagnostic reproducibility of squamous cell carcinoma (SC) in the era of histology-directed non-small cell lung cancer (NSCLC) chemotherapy: A large prospective study. (2016) (33)
Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancer (2003) (32)
Update on taxanes in the first-line treatment of advanced non-small-cell lung cancer. (2014) (32)
Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). (2010) (32)
Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose‐escalating conformal thoracic radiation therapy in unresectable Stage IIIA/B nonsmall cell lung carcinoma (2000) (32)
3073 Exploratory analysis of frontline therapies in REVEL: A randomized phase III study of ramucirumab (RAM) plus docetaxel (DOC) versus DOC for the treatment of stage IV non-small-cell lung cancer (NSCLC) after disease progression on platinum-based therapy (2015) (32)
Pure red blood cell aplasia associated with chronic Epstein-Barr virus infection: evidence for T cell-mediated suppression of erythroid colony forming units. (1984) (32)
Impact of preoperative chemotherapy on pulmonary function tests in resectable early-stage non-small cell lung cancer. (2008) (31)
Detection of retroperitoneal metastases in early-stage nonseminomatous testicular cancer: analysis of different CT criteria. (1987) (31)
Influenza and aging: Age-related changes and the effects of thymosin on the antibody response to influenza vaccine (1984) (30)
Paclitaxel poliglumex (PPX)/carboplatin vs paclitaxel/carboplatin for the treatment of PS2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): A phase III study (2005) (30)
IMpower131: Progression-free survival (PFS) and overall survival (OS) analysis of a randomised phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC. (2018) (29)
Cardiac synovial sarcoma with translocation (X; 18) associated with asbestos exposure (1994) (29)
Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105. (2011) (29)
Near complete response after single dose of nivolumab in patient with advanced heavily pre-treated KRAS mutant pulmonary adenocarcinoma (2015) (28)
Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment. (2015) (28)
Effect of gender on outcome in two randomized phase III trials of paclitaxel poliglumex (PPX) in chemonaïve pts with advanced NSCLC and poor performance status (PS2). (2006) (28)
LBA60 ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations (2020) (28)
Pemetrexed in Relapsed Small-Cell Lung Cancer and the Impact of Shortened Vitamin Supplementation Lead-In Time: Results of a Phase II Trial (2008) (28)
Post-chemotherapy gross tumor volume is predictive of survival in patients with stage III non-small cell lung cancer treated with combined modality therapy. (2006) (27)
Abstract CT216: IMpower150 final analysis: Efficacy of atezolizumab (atezo) + bevacizumab (bev) and chemotherapy in first-line (1L) metastatic nonsquamous (nsq) non-small cell lung cancer (NSCLC) across key subgroups (2020) (27)
Management of unresectable stage III non-small cell lung cancer: the role of combined chemoradiation. (2004) (27)
LBA38_PRDABRAFENIB IN PATIENTS WITH BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A MULTICENTER, OPEN-LABEL, PHASE II TRIAL (BRF113928) (2014) (27)
Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. (2012) (27)
Patient-Reported Neuropathy and Taxane-Associated Symptoms in a Phase 3 Trial of nab-Paclitaxel Plus Carboplatin versus Solvent-Based Paclitaxel Plus Carboplatin for Advanced Non–Small-Cell Lung Cancer (2014) (27)
RET Rearrangements in Lung Adenocarcinoma and Radiation (2014) (26)
Efficacy and safety of PF-00299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC). (2010) (26)
Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin. (2012) (26)
Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer (2020) (26)
Clinical efficacy of atezolizumab plus bevacizumab and chemotherapy in KRAS-mutated non-small cell lung cancer with STK11, KEAP1, or TP53 comutations: subgroup results from the phase III IMpower150 trial (2022) (26)
The current status and evolving role of sunitinib in non-small cell lung cancer. (2008) (26)
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC). (2017) (26)
Phase I trial of carboplatin and etoposide in combination with panobinostat in patients with lung cancer. (2013) (25)
The HSP90 Inhibitor Ganetespib Radiosensitizes Human Lung Adenocarcinoma Cells (2015) (25)
Maintenance Sunitinib following Initial Platinum‐Based Combination Chemotherapy in Advanced‐Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double‐Blind, Placebo‐Controlled Phase III Study—CALGB 30607 (Alliance) (2017) (25)
The clinical utility of PD‐L1 testing in selecting non‐small cell lung cancer patients for PD1/PD‐L1‐directed therapy (2016) (25)
Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer (2021) (25)
Consensus Report of a Joint NCI Thoracic Malignancies Steering Committee: FDA Workshop on Strategies for Integrating Biomarkers into Clinical Development of New Therapies for Lung Cancer Leading to the Inception of “Master Protocols” in Lung Cancer (2014) (25)
A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy. (2014) (24)
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. (2018) (24)
OA14.02 IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC (2019) (24)
Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses. (2015) (23)
The emerging role of biomarkers in advanced non-small-cell lung cancer. (2010) (23)
Phase I Trial of Nanoparticle Albumin-Bound Paclitaxel in Combination with Gemcitabine in Patients with Thoracic Malignancies (2008) (23)
134PD Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic NSCLC (IMpower150) (2018) (23)
Bevacizumab in the treatment of non-small-cell lung cancer (2007) (23)
Adjuvant therapy of resected non-small-cell lung cancer. (2004) (23)
Incorporating Immunotherapy Into the Treatment of Non-Small Cell Lung Cancer: Practical Guidance for the Clinic. (2015) (22)
Erlotinib in African Americans With Advanced Non–Small Cell Lung Cancer: A Prospective Randomized Study With Genetic and Pharmacokinetic Analyses (2014) (22)
Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B nonsmall cell lung carcinoma: a modified Phase I trial. (2000) (22)
Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation. (2014) (21)
Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer Symptom Scale (LCSS) (2009) (21)
Safety and efficacy of weekly nab®-paclitaxel in combination with carboplatin as first-line therapy in elderly patients with advanced non-small-cell lung cancer. (2013) (21)
Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. (2001) (21)
The impact of local and regional disease extent on overall survival in patients with advanced stage IIIB/IV non-small cell lung carcinoma. (2012) (21)
A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761). (2015) (21)
Quality of Life Analyses from the Randomized, Open-Label, Phase III PointBreak Study of Pemetrexed-Carboplatin-Bevacizumab followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non–Sm (2015) (21)
Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer. (2001) (20)
Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non-Small Cell Lung Cancer Treatment Setting. (2018) (20)
Second-line gemcitabine in refractory stage IV non small-cell lung cancer: a phase II trial. (2000) (20)
Acute pancreatitis associated with chemotherapy for germ cell tumors in two patients. (1988) (20)
Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC (2014) (19)
Current and evolving treatment options for limited stage small cell lung cancer (2006) (19)
IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations. (2018) (19)
Immunotherapy in lung cancer. (2014) (19)
Phase II Trial of Weekly Dose-Dense Paclitaxel in Extensive-Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Study 39901 (2008) (19)
1383TiPBlood first line ready screening trial (B-F1RST) and blood first assay screening trial (BFAST) enable clinical development of novel blood-based biomarker assays for tumor mutational burden (TMB) and somatic mutations in 1L advanced or metastatic NSCLC (2017) (19)
Hypersensitivity pneumonitis in advanced non-small-cell lung cancer patients receiving gemcitabine and paclitaxel: report of two cases and a review of the literature. (2002) (19)
Effect of expanded genomic testing in lung adenocarcinoma (LUCA) on survival benefit: The Lung Cancer Mutation Consortium II (LCMC II) experience. (2016) (19)
Carboplatin-based chemotherapy in patients with advanced non-small cell lung cancer and a poor performance status. (2006) (19)
Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20). (2021) (19)
Current Status and Future Implications (2011) (19)
Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer (2018) (18)
Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma (2002) (18)
The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial (2016) (18)
The role of chemotherapy in the treatment of unresectable stage III and IV nonsmall cell lung cancer. (2003) (18)
36MO Safety, tolerability and preliminary efficacy of poziotinib with twice daily strategy in EGFR/HER2 Exon 20 mutant non-small cell lung cancer (2021) (18)
Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in Patients with Early-Stage Non-small Cell Lung Cancer (2005) (18)
Clinical issues in the management of non-small-cell lung cancer and the role of platinum-based therapy. (2004) (18)
Is there a role of nab-paclitaxel in the treatment of advanced non-small cell lung cancer? The data suggest yes. (2016) (18)
Novel agents in the treatment of lung cancer: conference summary statement. (2004) (18)
Incorporation of bevacizumab (B) and erlotinib (Er) with induction (Ind) and concurrent (Conc) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLC). (2008) (18)
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials. (2007) (18)
Estrogen-receptor-related protein p29 in primary nonsmall cell lung carcinoma: pathologic and prognostic correlations. (1998) (17)
Induction therapy with carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal radiotherapy in the treatment of locally advanced, unresectable non-small cell lung cancer: preliminary report of a phase I trial. (1997) (17)
1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations (2020) (17)
Summary Statement Novel Agents in the Treatment of Lung Cancer: Fifth Cambridge Conference Assessing Opportunities for Combination Therapy (2008) (16)
Immune checkpoint blockade in lung cancer. (2016) (16)
An open label phase II trial of the Plk1 inhibitor BI 2536, in patients with sensitive relapse small cell lung cancer (SCLC). (2009) (16)
The evolving role of pemetrexed (Alimta) in lung cancer. (2005) (16)
Single-agent paclitaxel and paclitaxel/non-platinum combination therapy in advanced non-small cell lung cancer. (1999) (16)
Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150. (2021) (16)
EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study (2017) (16)
Combined modality therapy for stage III non-small cell lung cancer. (2006) (16)
A retrospective analysis of outcomes across histological subgroups in a three-arm phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. (2010) (15)
2LB Phase III, randomized, open-label, parallel-group study of oral gefitinib (IRESSA) versus intravenous docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who have previously received platinum- based chemotherapy (INTEREST) (2007) (15)
Personalizing Therapy in Advanced Non–Small Cell Lung Cancer (2013) (15)
A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (abraxane) in patients with extensive-stage small cell lung cancer. (2015) (15)
Duration of therapy in advanced, metastatic non-small-cell lung cancer. (2003) (15)
MA16.09 Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer (2017) (15)
Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation. (2002) (15)
Abstract CT076: IMpower150: Efficacy of atezolizumab (atezo) plus bevacizumab (bev) and chemotherapy (chemo) in 1L metastatic nonsquamous NSCLC (mNSCLC) across key subgroups (2018) (15)
Beliefs among Physicians in the Diagnostic and Therapeutic Approach to Non-small Cell Lung Cancer (2007) (15)
Re-evaluating duration of therapy in advanced non-small-cell lung cancer: is it really duration or is it more about timing and exposure? (2009) (15)
Molecular and Immune Biomarker Testing in Squamous‐Cell Lung Cancer: Effect of Current and Future Therapies and Technologies (2018) (14)
Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non–Small‐Cell Lung Cancer (2017) (14)
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer. (2018) (14)
1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations (2020) (14)
Treatment of gefitinib-associated folliculitis. (2006) (14)
3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement (2015) (14)
Necitumumab plus Gemcitabine and Cisplatin as First-Line Therapy in Patients with Stage IV EGFR- Expressing Squamous Non-Small-Cell Lung Cancer: German Subgroup Data from an Open-Label, Randomized Controlled Phase 3 Study (SQUIRE) (2016) (14)
Pharmacogenomic analysis from a phase III study of pemetrexed plus carboplatin (PC) versus etoposide plus carboplatin (EC) in chemonaive patients (pts) with extensive-stage disease small cell lung cancer (ED-SCLC). (2009) (14)
The Feasibility of Adjuvant Carboplatin and Docetaxel in Patients with Curatively Resected Non-small Cell Lung Cancer (2008) (14)
Update on nanoparticle albumin-bound paclitaxel. (2006) (13)
Personalized therapy for non-small cell lung cancer: which drug for which patient? (2011) (13)
MO06.12 Efficacy and safety of paclitaxel and carboplatin with bevacizumab for the first-line treatment of patients with nonsquamous non-small cell lung cancer (NSCLC): analyses based on age in the phase 3 PointBreak and E4599 trials. (2013) (13)
Survival results of a randomized, phase III trial of nab-paclitaxel and carboplatin compared with cremophor-based paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer. (2011) (13)
MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer (2017) (13)
Pure RBC aplasia and myasthenia gravis. Coexistence of two diseases associated with thymoma. (1983) (13)
Initial Pulmonary Toxicity Evaluation of Chemoradiotherapy (CRT) Utilizing 74 Gy 3-Dimensional (3-D) Thoracic Radiation in Stage III Non-Small Cell Lung Cancer (NSCLC): A Cancer and Leukemia Group B (CALGB) Randomized Phase II Trial (2005) (13)
Nab‐paclitaxel in older patients with non–small cell lung cancer who have developed disease progression after platinum‐based doublet chemotherapy (2020) (13)
A phase III, randomized, open-label trial of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator's choice chemotherapy (ICC) as first-line therapy for stage IV or recurrent PD-L1+ non-small cell lung cancer (NSCLC). (2014) (13)
Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium. (2001) (13)
41 Clinical activity of BIND-014 (docetaxel nanoparticles for injectable suspension) as second-line therapy in patients (pts) with Stage III/IV non-small cell lung cancer (2014) (12)
Novel Agents in the Treatment of Lung Cancer (2004) (12)
Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20). (2022) (12)
P3.02b-001 Phase 1 Dose Escalation of PF-06747775 (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R+/-T790M) NSCLC: Topic: EGFR Biomarkers (2017) (12)
Patient-reported outcomes (PROs) in the randomized, phase III IMpower150 study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous metastatic NSCLC (mNSCLC). (2018) (12)
If histology matters... (2010) (12)
The role of induction therapy in the management of resectable non-small cell lung cancer. (2000) (12)
Analysis of prognostic factors in patients with advanced relapsed/refractory NSCLC: Cox regression analysis of a randomized phase III trial comparing docetaxel and paclitaxel poliglumex (PPX). (2006) (12)
RANDOMIZED PHASE II STUDY OF SUNITINIB (SU) PLUS ERLOTINIB (E) VS. PLACEBO (P) PLUS E FOR THE TREATMENT OF METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) (2010) (11)
Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC). (2021) (11)
Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference (2007) (11)
Second-line (SL) weekly paclitaxel (P) in patients (pts) with advanced non-small cell lung cancer (NSCLC) failing first-line (FL) carboplatin/paclitaxel (C/P) (2000) (11)
Assessing response to treatment in non--small-cell lung cancer: role of tumor volume evaluated by computed tomography. (2014) (11)
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients. (2011) (11)
Phase I trial of topotecan (T) carboplatin (C) and etoposide (E) for extensive stage small cell lung cancer (ES-SCLC) (2000) (11)
A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer. (2006) (11)
The current status of adjuvant chemotherapy for resected non-small cell lung cancer. (1999) (11)
Final results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) + Cb as first-line treatment of patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). (2009) (11)
Seeking new options for the treatment of small-cell lung cancer. (2005) (11)
Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer. (2020) (11)
Simultaneous FDG PET+/Glut1+ lung and FDG PET−/Glut1− subcarinal lymph node metastases from prostate cancer (2009) (10)
Combined modality trials in unresectable stage III non-small cell lung cancer: the Cancer and Leukemia Group B experience. (2005) (10)
Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients. (1998) (10)
IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets) (2019) (10)
EGFR IHC and FISH Correlative Analyses (SQUIRE Trial): necitumumab plus gemcitabine-cisplatin vs gemcitabine-cisplatin in 1st-line squamous NSCLC (2015) (10)
Coexistent breast and vaginal granulocytic sarcoma. (1983) (10)
Preliminary results of a randomized phase II trial of pemetrexed (P) + carboplatin (Cb) ± enzastaurin (ENZ) versus docetaxel (D) + Cb as first-line treatment of patients with stage IIIB/IV non-small cell lung cancer (NSCLC) (2008) (10)
Phase Ib Study of Bavituximab With Carboplatin and Pemetrexed in Chemotherapy‐Naive Advanced Nonsquamous Non–Small‐Cell Lung Cancer (2018) (10)
Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma. (2020) (10)
Weekly nab-Paclitaxel in Combination With Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Analysis of Safety and Efficacy in Patients With Diabetes. (2016) (9)
High-dose 3D chemoradiotherapy trials in stage III non-small cell lung cancer (NSCLC) at the University of North Carolina: Long-term follow up and late complications. (2006) (9)
IMpower150: Exploratory analysis of brain metastases development. (2020) (9)
Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. (2017) (9)
Phase II trial of paclitaxel, ifosfamide, and carboplatin in extensive-stage small cell lung cancer. (2003) (9)
LBA46 Efficacy and safety of poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations: A multinational phase II study (ZENITH20-4) (2021) (9)
O-217 A randomized phase III trial of gemcitabine (G) in combination with carboplatin (C) or paclitaxel (P) versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) Non-Small Cell Lung Cancer (NSCLC) (2003) (9)
Pemetrexed (Alimta) in small cell lung cancer. (2005) (9)
Phase II study of the AKT inhibitor MK-2206 plus erlotinib (E) in patients (pts) with advanced non-small cell lung cancer (NSCLC) who progressed on prior erlotinib: A California Cancer Consortium Phase II trial (NCI 8698). (2014) (9)
Paradoxical functions of ZEB1 in EGFR-mutant lung cancer: tumor suppressor and driver of therapeutic resistance. (2016) (9)
Sunitinib (S) switch maintenance in advanced non-small cell lung cancer (NSCLC): An ALLIANCE (CALGB 30607), randomized, placebo-controlled phase III trial. (2014) (9)
CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC). (2012) (8)
Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): Preliminary report of Cancer and Leukemia Group B (CALGB) 30105. (2006) (8)
Targeted therapies: Biomarkers in NSCLC for selecting cetuximab therapy (2010) (8)
Induction (I) and concurrent (C) carboplatin/paclitaxel (C/P) with dose escalated thoracic conformal radiotherapy (TCRT) in stage IIIA/B non-small cell lung cancer (NSCLC): A phase I/II trial (2000) (8)
Specific antibody synthesis in vitro. III. Correlation of in vivo and in vitro antibody response to influenza immunization in young and old subjects. (1985) (8)
O-183 A phase III study of surgical resection and chemotherapy (paclitaxel/carboplatin) (CT) with or without adjuvant radiation therapy (RT) for resected stage III non-small cell lung cancer (NSCLC): CALGB 9734 (2003) (8)
1358PFirst-in-human phase I study of PF-06747775, a third-generation mutant selective EGFR tyrosine kinase inhibitor (TKI) in metastatic EGFR mutant NSCLC after progression on a first-line EGFR TKI (2017) (8)
Phase II randomized trial of irinotecan/docetaxel (ID) or irinotecan/gemcitabine (IG) with or without celecoxib (CBX) in 2nd-line treatment of non-small-cell lung cancer (NSCLC). (2004) (8)
Abstract CT194: Exploratory subgroup analysis of atezolizumab (atezo) clinical characteristics in patients (pts) with low circulating tumor DNA (ctDNA) in B-F1RST—a Phase II trial evaluating blood-based tumor mutational burden (bTMB) in NSCLC (2019) (8)
Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (2020) (8)
Phase I/II trial of bevacizumab (B) and erlotinib (E) with induction (IND) and concurrent (CON) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer (NSCLC). (2011) (8)
Phase III clinical trials in chemotherapy-naive patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapy (2016) (8)
EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor. (2018) (8)
A Multicenter Phase II Trial of Carboplatin and Cetuximab for Treatment of Advanced Nonsmall Cell Lung Cancer (2009) (8)
Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former/Light Smoking Patients With Stage IV Non-Small Cell Lung Cancer. (2016) (7)
Pemetrexed (P) in relapsed small cell lung cancer (SCLC): Preliminary results of a phase II trial (2007) (7)
375O Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC (2020) (7)
Does more aggressive therapy improve outcomes in the treatment of unresectable stage III non-small cell lung cancer? (2005) (7)
Bevacizumab as first-line treatment for advanced non-small cell lung cancer. (2008) (7)
Predicting the need for palliative thoracic radiation after first‐line chemotherapy for advanced nonsmall cell lung carcinoma (2012) (7)
A phase II trial of weekly paclitaxel and gemctiabine infused at a constant rate in patients with advanced non-small cell lung cancer. (2005) (7)
Dose escalation study of nab-paclitaxel followed by carboplatin as first line therapy in advanced non-small cell lung cancer (NSCLC). (2006) (7)
nab-paclitaxel/carboplatin induction in squamous NSCLC: longitudinal quality of life while on chemotherapy (2017) (7)
Randomized phase II trial of pemetrexed with either cisplatin or carboplatin in extensive stage small cell lung cancer (2004) (7)
A Comparison of White and African American Outcomes from a Three-Arm, Randomized, Phase III Multicenter Trial of Advanced or Metastatic Non-small Cell Lung Cancer (2010) (7)
O-101 XYOTAX™/carboplatin vs paclitaxel/carboplatin for the treatmentof PS2 patients with chemotherapy-naïve advanced non-small cell lung cancer (NSCLC): The stellar 3 phase III study (2005) (7)
The prognostic value of KRAS mutation subtypes and PD-L1 expression in patients with lung adenocarcinoma. (2019) (7)
Radiation-induced sarcoma after high-dose thoracic radiation therapy in non-small-cell lung cancer. (2007) (7)
A phase 2 study of poziotinib in patients with EGFR or HER2 exon 20 mutation-positive non-small cell lung cancer. (2018) (6)
PS01.53: First‐Line Atezolizumab Plus Chemotherapy in Chemotherapy‐Naive Patients with Advanced NSCLC: A Phase III Clinical Program: Topic: Medical Oncology (2016) (6)
A meta-analysis evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small cell lung cancer (2003) (6)
nab-Paclitaxel/carboplatin in elderly patients with advanced squamous non-small cell lung cancer: a retrospective analysis of a Phase III trial (2018) (6)
Painless diarrhea secondary to intestinal ischemia. Diagnosis of atheromatous emboli by jejunal biopsy (1984) (6)
Atezolizumab Treatment of Nonsquamous NSCLC. (2018) (6)
Treatment of surgically resectable non-small-cell lung cancer in elderly patients. (2009) (6)
A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer (2015) (6)
Combined-modality therapy in the nonsurgical management of unresectable stage III non-small cell lung cancer. (1999) (6)
Drug development in patients with advanced non-small cell lung cancer and poor performance status. (2004) (6)
Best Practices in Treatment Selection for Patients With Advanced NSCLC. (2016) (6)
Inherited Variation in the ATP-Binding Cassette Transporter ABCB1 and Survival after Chemotherapy for Stage III–IV Lung Cancer (2014) (6)
MA 19.03 Nintedanib + Pemetrexed/Cisplatin in Malignant Pleural Mesothelioma (MPM): Phase II Biomarker Data from the LUME-Meso Study (2017) (6)
Phase II trial of carboplatin plus cetuximab for the treatment of stage IIIB/IV non-small cell lung cancer (NSCLC) (2007) (5)
103PDSUBGROUP ANALYSIS OF ELDERLY PATIENTS IN SQUIRE: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III STUDY OF NECITUMUMAB (N) PLUS GEMCITABINE-CISPLATIN (GC) CHEMOTHERAPY VERSUS GC ALONE IN FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER (SQ-NSCLC) (2015) (5)
Induction chemotherapy followed by dose-escalated thoracic 3-dimensional conformal radiation therapy to 90 Gy with concurrent chemotherapy in stage IIIA/B non-small cell lung cancer: a phase I radiation dose escalation trial (2003) (5)
Nintedanib plus Pemetrexed/Cisplatin in Patients with MPM: Phase II Findings from the Placebo-Controlled LUME-Meso Trial (2017) (5)
PD3-3-8: A phase II study of continuous daily sunitinib dosing in patients with previously-treated advanced non-small cell lung cancer (NSCLC) (2007) (5)
AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC). (2021) (5)
P-585 Long-term results of aggressive combined modality therapy employing induction and concurrent carboplatin/paclitaxel with dose-escalated thoracic conformal radiation therapy (2003) (5)
OA 14.07 Progress in Lung Squamous Cell Carcinoma from the Lung-MAP Master Protocol (S1400) Sub-Studies S1400A, S1400B, S1400C and S1400D (2017) (5)
Association between depth of response and survival in patients with advanced‐stage non–small cell lung cancer treated with first‐line chemotherapy (2019) (5)
Alternative strategy to achieve increased overall survival and better quality of life in patients with second-line advanced non-small-cell lung cancer. (2015) (5)
Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC) (2007) (5)
O-70 Timing of thoracic radiation therapy in combined modality therapy for limited-stage small cell lung cancer: A meta-analysis (2003) (5)
Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer (2018) (5)
Title: Lung squamous cell carcinoma mRNA expression subtypes are reproducible, clinically-important and correspond to different normal cell types (2010) (5)
Preliminary results of a randomized phase II trial of first-line treatment of gemcitabine (G) versus erlotinib (E) versus gemcitabine and erlotinib (GE) in patients 70 years or older with advanced non-small cell lung cancer (NSCLC). (2010) (5)
Impact of the ASCO 2007 Presentation of HOG Lun 01-24/USO-023 on the Prescribing Plans of American Medical Oncologists for Patients with Stage IIIB Non-small Cell Lung Cancer (2009) (5)
Randomized phase 3 trial of amrubicin versus topotecan as second-line treatment for small cell lung cancer (SCLC) (2012) (5)
IMpower150: An exploratory analysis of efficacy outcomes in patients with EGFR mutations. (2018) (5)
Preliminary safety and efficacy data of a phase II trial of vinflunine and cetuximab in the second-line treatment of patients with advanced non-small cell lung cancer (2008) (5)
Exploratory analyses of efficacy and safety of pemetrexed (Pem) plus bevacizumab (Bev) and bev alone as maintenance therapy (MT) in patients (Pts) with stage IIIb or IV nonsquamous non-small cell lung cancer (NS-NSCLC). (2013) (5)
Elderly subgroup analysis of a randomized phase 3 trial of gemcitabine (G) in combination with carboplatin (Cb) or paclitaxel (P) compared to paclitaxel plus carboplatin in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC) (2007) (5)
START2: Tecemotide in unresectable stage III NSCLC after first-line concurrent chemoradiotherapy. (2014) (5)
High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer. (1997) (5)
Do oncogenic drivers exist in squamous cell carcinoma of the lung? (2013) (5)
MA08.01 A Highly Sensitive Next-Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma (2017) (5)
A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. (2018) (4)
A Multicenter Phase II Study of Ganetespib Monotherapy in Patients with Genotypically De fi ned Advanced Non – Small Cell Lung Cancer (2013) (4)
Abstract PO-003: CRESTONE – Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) Fusions – A phase 2 study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210) (2020) (4)
Nanoparticle Albumin-bound Paclitaxel Plus Carboplatin Induction Followed by Nanoparticle Albumin-bound Paclitaxel Maintenance in Squamous Non-Small-cell Lung Cancer (ABOUND.sqm): A Phase III Randomized Clinical Trial. (2020) (4)
A single arm, open-label, phase II study to assess the efficacy of lucitanib in patients with FGFR1-amplified squamous NSCLC (sqNSCLC). (2014) (4)
Phase III double-blind study comparing the efficacy and safety of proposed biosimilar MYL-1402O and reference bevacizumab in stage IV non-small-cell lung cancer (2021) (4)
Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung C (2015) (4)
Subgroup analysis of African American patients from a randomized phase 3 trial of gemcitabine (G) in combination with carboplatin (Cb) or paclitaxel (P) compared to P plus Cb in advanced (stage IIIB, IV) non-small cell lung cancer (NSCLC) (2007) (4)
Phase I/II trial of irinotecan, carboplatin, and paclitaxel in advanced or metastatic NSCLC. (2000) (4)
A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer. (2019) (4)
A bioequivalence study of proposed bevacizumab biosimilar, MYL-1402O (A) vs EU-Avastin (B) and US-Avastin (C). (2017) (4)
Advances in Immuno-Oncology: Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer-Introduction. (2015) (4)
P90.03 A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (2021) (4)
A randomized phase II trial of pemetrexed (P) plus cisplatin (cis) or carboplatin (carbo) in extensive stage small cell lung cancer (ES-SCLC) (2005) (4)
MA11.04 Updated Efficacy, Safety and Dosing Management of Poziotinib in Previously Treated EGFR and HER2 Exon 20 NSCLC Patients (2021) (4)
A pharmacokinetics study of proposed bevacizumab biosimilar MYL-1402O vs EU-bevacizumab and US-bevacizumab (2021) (4)
Chemotherapeutic issues in the management of unresectable stage III non-small cell lung cancer. (2005) (4)
Immune Checkpoint Blockade in Oncogene-Driven Non-Small-Cell Lung Cancer (2020) (4)
A single-arm, open-label, phase 2 study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer (NSCLC) (2016) (4)
IMpower132: A phase III clinical program—1L atezolizumab plus platinum-based chemotherapy in chemo-naive advanced non-squamous NSCLC. (2017) (4)
Biomarker Associations With Survival for Refractory NSCLC Patients Receiving Erlotinib +/- Sunitinib in a Randomized Phase 2 Trial (2010) (4)
Abstract CT081: Poziotinib activity and durability of responses in previously treated EGFR exon 20 NSCLC patients - a Phase 2 study (2020) (4)
Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in elderly patients (pts) with advanced non-small cell lung cancer (NSCLC). (2012) (4)
Analysis of prognostic factors in chemo-naïve patients with advanced NSCLC and poor performance status (PS): Cox regression analysis of two phase III trials. (2006) (4)
nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis (2021) (4)
Radiologic evaluation of nonseminomatous germ cell tumor of the testis. (1988) (4)
Irinotecan (CPT-11) in triplet combinations in patients with advanced non small-cell lung cancer: a review and report of a phase I/II trial. (2001) (4)
PD-076 Phase II randomized trial of irinotecan/docetaxel oririnotecan/gemcitabine with or without celecoxib in 2nd-line treatment of non-small-cell lung cancer (2005) (4)
Metastasis of Breast Carcinoma to the Maxillary Sinus (2014) (4)
Abstract CT169: Poziotinib administered twice daily improves safety and tolerability in patients with EGFR or HER2 exon 20 mutant NSCLC(ZENITH20-5) (2021) (4)
Randomized Phase 2 Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Single-Agent Chemotherapy in Previously Treated KRAS Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) (2014) (3)
Targeted therapy vs chemotherapy: which has had more impact on survival in lung cancer? The significant impact of chemotherapy in lung cancer. (2014) (3)
Elung: A Multicenter, Randomized Phase IIB Trial of “Standard” Platinum Doublets Plus Cetuximab (CET) as First-Line Treatment of Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) (2012) (3)
Clinical roundtable monograph: Recent advances in taxanes for the first-line treatment of advanced non-small cell lung cancer. (2012) (3)
Subgroup analyses by performance status (PS) in the phase III SQUIRE study: First-line necitumumab (N) plus gemcitabine-cisplatin (GC) vs. GC in squamous non-small cell lung cancer (NSCLC). (2015) (3)
Irinotecan in non-small-cell lung cancer: status of ongoing trials. (2002) (3)
MA07.01 Updated Pooled Analysis of CNS Endpoints in Two Phase II Studies of Alectinib in ALK+ NSCLC (2017) (3)
Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC. (2016) (3)
Neoadjuvant carboplatin/paclitaxel (CP) followed by concurrent CP and dose escalating thoracic conformal radiation therapy (TCRT) in stage III non-small cell lung cancer (NSCLC): a phase I/II trial (1998) (3)
PS01.54: Evaluation of Novel Blood‐Based Biomarkers with Atezolizumab Monotherapy in 1L Advanced or Metastatic NSCLC (B‐F1RST): Topic: Medical Oncology (2016) (3)
MA08.06 Impact of Depth of Response (DpR) on Survival in Patients with Advanced NSCLC Treated with First-Line Chemotherapy (2017) (3)
A comparative clinical study of PF-06439535, a candidate bevacizumab biosimilar, and reference bevacizumab, in patients with advanced non-squamous non-small cell lung cancer. (2018) (3)
IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC. (2018) (3)
A study of rovalpituzumab tesirine in frontline treatment of patients with DLL3 expressing extensive small cell lung cancer. (2017) (3)
Switch Maintenance With Sunitinib (S) in Advanced Non-Small Cell Lung Cancer (NSCLC): An Alliance (CALGB 30607), Randomized, Placebo-Controlled Phase 3 Trial (2014) (3)
PD4-1-2: Incorporation of bevacizumab (B) and erlotinib (Er) with induction (I) and concurrent (C) carboplatin (Cb)/paclitaxel (P) and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer (NSCLS): preliminary report of a phase I/II trial (2007) (3)
1232PSQUIRE: A RANDOMIZED, MULTICENTER, OPEN-LABEL, PHASE III STUDY OF GEMCITABINE-CISPLATIN (GC) CHEMOTHERAPY PLUS NECITUMUMAB (IMC-11F8/LY3012211) VS GC ALONE IN THE FIRST-LINE TREATMENT OF PATIENTS (PTS) WITH STAGE IV SQUAMOUS NON-SMALL CELL LUNG CANCER (SQ-NSCLC): UPDATE ON KEY SUBGROUPS. (2014) (3)
CNS activity of poziotinib in NSCLC with exon 20 insertion mutations. (2021) (3)
Randomized phase III trial of gemcitabine/carboplatin with or without iniparib (BSI-201) in patients with previously untreated stage IV squamous non-small cell lung cancer (NSCLC). (2011) (3)
Phase I study of rilotumumab (AMG 102), an HGF inhibitor, and erlotinib in patients with advanced non-small cell lung cancer (NSCLC). (2014) (3)
Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC). (2020) (3)
Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): Analysis of patient-reported neuropathy and taxane-associated symptoms. (2012) (3)
Phase II Study of Continuous Daily Sunitinib Dosing in Patients with Previously Treated Advanced Non–Small-Cell Lung Cancer (NSCLC) (2007) (3)
B2-04: Single agent versus combination therapy in advanced NSCLC patients with performance status 2: Results from a regression analysis of STELLAR 3 and 4 (2007) (2)
CRESTONE: Clinical study of response to seribantumab in tumors with neuregulin-1 (NRG1) fusions—A phase II study of the anti-HER3 mAb for advanced or metastatic solid tumors (NCT04383210). (2021) (2)
Randomized phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small cell lung cancer (NSCLC) (2007) (2)
P1.16-04 Outcomes of Patients <70 or ≥70 Years of Age in PACIFIC (2018) (2)
The Role of Induction Therapy for Resectable Non-Small Cell Lung Cancer (2012) (2)
Randomized phase II trial comparing every-3-week carboplatin/paclitaxel (C/P) versus every-3-week C with weekly P in advanced non-small cell lung cancer (NSCLC). (2004) (2)
GALAXY-2 trial: A randomized phase III study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced non-small cell lung adenocarcinoma. (2013) (2)
O-115 Induction chemotherapy with gemcitabine-containing regimensin stage I–II non-small cell lung cancer (NSCLC): Initial results of the GINEST* Project (2005) (2)
Maximum severity score (MSS) of baseline patient-reported Lung Cancer Symptom Scale (LCSS) as a prognostic and predictive factor for overall survival (OS) in the Phase III SQUIRE study. (2015) (2)
nab-paclitaxel + carboplatin induction followed by nab-paclitaxel maintenance in squamous non-small cell lung cancer (NSCLC): Results from the ABOUND.sqm study. (2018) (2)
An analysis of the prevalence of HER2 and KRAS mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC). (2013) (2)
Gemcitabine-based combinations as preoperative therapy in resectable non-small-cell lung cancer. (2003) (2)
A pooled analysis of concurrent chemoradiotherapy (CCRT) for patients with stage III non-small cell lung cancer (NSCLC) who participated in U.S. Cooperative Group Trials: comparing the outcomes of elderly to younger patients (pts) (2016) (2)
Failure patterns of nonseminomatous testicular germ cell tumors: radiographic analysis of 51 cases. (1988) (2)
Phase III Trial Comparing Paclitaxel Poliglumex (CT-2103, PPX) in Combination with Carboplatin Versus Standard Paclitaxel and Carboplatin in the Treatment of PS 2 Patients with Chemotherapy-Naı¨ve Advanced Non-small Cell Lung Cancer (2008) (2)
Phase III trial of paclitaxel (P), carboplatin (C), and irinotecan (CPT-11), in advanced or metastatic non-small-cell lung cancer (NSCLC) (1998) (2)
26MO Efficacy and safety of poziotinib in treatment-naïve HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4 (2022) (2)
A phase I/II trial of weekly docetaxel and gefitinib in elderly patients (≥ 70) with stage IIIB/IV non-small cell lung cancer (NSCLC) (2005) (2)
Rash as a marker for the efficacy of necitumumab in the SQUIRE Study (2015) (2)
356TiPPhase III clinical trials of atezolizumab in combination with chemotherapy in chemotherapy-naive patients with advanced NSCLC (2015) (2)
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer (2023) (2)
A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors (2022) (1)
P-251 Randomized phase II trial of weekly carboplatin/paclitaxel (C/P) versus every-3-week C/P in advanced non-small cell lung cancer (NSCLC): A pure schedule trial (2003) (1)
96-Hour Paclitaxel Infusions: At Least 93 Hours Too Long (2003) (1)
Analysis of Predictive Factors in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) as First-Line Therapy for Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC) (2014) (1)
Inter-observer reliability for the diagnosis of lung cancer in a clinical cohort using the WHO classification system, version (2008) (1)
6525 POSTER Phase II study investigating the efficacy and safety of continuous daily sunitinib dosing in previously treated advanced non-small cell lung cancer (NSCLC) (2007) (1)
O-234 The role of singlet (1CR) vs. doublet (2CR) vs. triplet (3CR) chemotherapy regimens in stage IIIB/IV non-small lung cancer (NSCLC): A meta-analysis of the published literature (2003) (1)
Incidence and outcomes associated with brain metastases (BM) in a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). (2009) (1)
Interim safety results from the phase 2 ABOUND.PS2 study evaluating nab-paclitaxel (nab-P) + carboplatin (C) followed by nab-P monotherapy in patients (pts) with NSCLC and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 (2016) (1)
GEMSTONE-302: "If you keep doing the same thing you get the same result". (2022) (1)
Migration to next-generation sequencing and the identification of RET and ROS1 rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0). (2015) (1)
Mature overall survival (OS) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). (2017) (1)
Neoadjuvant chemotherapy with gemcitabine-containing regimens in stage I-II non-small cell lung cancer (NSCLC): Initial results of pre-operative pulmonary function testing (PFTs) in the GINEST project (2005) (1)
P1.48: nab-Paclitaxel + Carboplatin in Advanced Non-Small Cell Lung Cancer: Outcomes in Elderly Patients With Squamous Histology: Track: Advanced NSCLC. (2016) (1)
A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer (2022) (1)
A prospective evaluation of quality of life (QOL) in a phase II trial of pemetrexed (P) plus carboplatin (Cb) ± enzastaurin (E) versus docetaxel (D) plus Cb as first-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). (2016) (1)
1391P Phase III confirmatory efficacy and safety study of proposed bevacizumab biosimilar (MYL-1402O) compared with avastin, in the first-line treatment of patients with stage IV non-squamous non-small cell lung cancer (nsNSCLC) (2020) (1)
Phase I trial of induction and concurrent chemotherapy with dose-escalated thoracic conformal radiation therapy (TCRT) to 78 Gy and beyond in unresectable stage III A/B non small cell lung cancer (NSCLC) (2002) (1)
Efficacy and safety of necitumumab continuation therapy in phase 3 SQUIRE study (2015) (1)
Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers. (2016) (1)
Randomized phase II trial of pemetrexed with either cisplatin or carboplatin in extensive stage small cell lung cancer. (2004) (1)
MA16.10 Lung-MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates (2017) (1)
Induction chemotherapy using carboplatin (C), irinotecan (I), and paclitaxel (P) with pegfilgrastim support followed by concurrent thoracic conformal radiation therapy (TCRT) with weekly CP and daily gefitinib (2005) (1)
P3.02c-038 First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naïve Patients with Advanced NSCLC: A Phase III Clinical Program: Topic: IT (2016) (1)
Phase II trial of gemcitabine as second line therapy for non-small cell lung cancer (NSCLC) (1998) (1)
The impact of shortened vitamin supplementation lead-in time before pemetrexed (P) in patients with relapsed small-cell lung cancer (SCLC): P1-229 (2007) (1)
Management of N3 stage IIIB NSCLC: Changes in US physician behavior following ASCO 2007 (2008) (1)
1267PQUALITY-OF-LIFE (QOL), TOLERABILITY, AND SUPPORTIVE CARE RESULTS: NECITUMUMAB PHASE 3 SQUIRE STUDY. (2014) (1)
O-6 Phase II randomized trial of irinotecan/docetaxel (ID) or irinotecan/gemcitabine (IG) with or without celecoxib in second-line non-small cell lung cancer (NSCLC) — preliminary results (2003) (1)
Safety and Efficacy of Necitumumab (N) During Single-Agent Treatment to Progression Following Gemcitabine-Cisplatin (GC) Chemotherapy Plus Necitumumab (IMC-11F8/LY3012211) in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (sq-NSCLC) (SQUIRE) (2014) (1)
A Phase I Trial Defining the Maximum Tolerated Systemic Exposure of Topotecan in Combination with Carboplatin and Etoposide in Extensive Stage Small Cell Lung Cancer (2005) (1)
Abstract B295: A Phase Ib study of bavituximab plus carboplatin and pemetrexed in chemotherapy-naïve incurable stage IIIb/IV non-squamous non-small cell lung cancer. (2013) (1)
O-038 Initial pulmonary toxicity evaluation of chemoradiotherapy (CRT) utilizing 74 Gy 3-dimensional (3-D) thoracic radiation in stage III non-small cell lung cancer (NSCLC): A Cancer and Leukemia Group B (CALGB) randomized phase II trial (2005) (1)
Hypomagnesaemia and its management following treatment with anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs): Results from 3 randomized studies of necitumumab (NECI) plus chemotherapy in first-line treatment of patients with stage IV non-small cell lung cancer (NSCLC) (2016) (1)
Analysis of Outcomes in Diabetic Patients in a Phase 3 Trial of Nab-Paclitaxel (nab-P) Plus Carboplatin (C) in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (2014) (1)
Safety and efficacy of necitumumab continuation therapy: Subgroup analysis of phase 3 SQUIRE study. (2015) (1)
Safety and ef fi cacy of weekly nab ®-paclitaxel in combination with carboplatin as fi rst-line therapy in elderly patients with advanced non-small-cell lung cancer (1)
A phase II, multicenter evaluation of docetaxel, gemcitabine, and bevacizumab followed by bevacizumab alone in patients with locally advanced or metastatic non-small cell lung cancer (central localization excluded) (2008) (1)
E-75.Optimal number of cytotoxic agents and chemotherapy cycles for advanced NSCLC (2003) (1)
A phase 3b safety study of fixed-dose durvalumab + tremelimumab or durvalumab monotherapy in advanced solid malignancies (STRONG): Urothelial and non-urothelial urinary tract carcinoma module A. (2018) (1)
The Use of Antiangiogenic Agents for Lung Cancer in Elderly Patients: An Expert Panel Discussion Synopsis. (2017) (1)
Does time to progression (TTP) influence post-progression survival (ppOS)?: Analyses from the PointBreak, ECOG 4599, and ARIES studies of bevacizumab in non–small cell lung cancer (NSCLC). (2015) (1)
The Effect of Necitumumab in Combination with Gemcitabine-Cisplatin on Health-Related Quality of Life (HRQOL) and Tolerability: Squire Trial Patients with Epidermal Growth Factor Receptor (EGFR)-Expressing Squamous NSCLC Tumours (2016) (1)
Serum and tumor biomarkers to predict outcome in the eLung trial, a multicenter, randomized phase IIb study of standard platinum doublets (PD) plus cetuximab (CET) as first-line treatment of advanced non-small cell lung cancer (NSCLC). (2013) (1)
P-576 A phase I/II trial of weekly docetaxel and gefitinib in elderlypatients (⩾70) with stage IIIB/IV non-small cell lung cancer (NSCLC) (2005) (1)
The Applicability of the Results in the Asian Population of ORIENT-11 to a Western Population According to the ICH-E5 Framework (2022) (1)
Emerging Applications of Positron Emission Tomography Imaging in the Management of Patients With Lung Cancer (2015) (1)
MA07.02 Evaluating Circulating Tumor DNA to Predict Overall Survival Risk in Non-Squamous Non-Small Cell Lung Cancer in IMpower150 (2021) (1)
An overview of adjuvant chemotherapy for resected non-small cell lung cancer: focus on the ECOG 1505 phase III trial (2008) (1)
T cells and erythroid burst forming units in chronic lymphocytic leukemia (1984) (1)
Phase II randomized study of the safety, efficacy, metabolism, and molecular targets of erlotinib in African Americans (AA) with NSCLC. (2010) (1)
The impact of shortened vitamin supplementation lead-in time before pemetrexed (P) in patients with relapsed small cell lung cancer (SCLC) (2007) (1)
The emergence of a unique population in non-small cell lung cancer: systemic or loco-regional relapse following postoperative adjuvant platinum-based chemotherapy. (2006) (1)
The impact of neoadjuvant chemotherapy and surgery on quality of life (QL) in patients with early stage NSCLC: A prospective analysis of the GINEST project (2005) (1)
First comprehensive report of impact of genomic alterations, chemotherapy, targeted therapy and immunotherapy on outcomes in the genomics driven squamous master protocol LungMAP. (2018) (1)
Chemotherapy helps patients with advanced non-small cell carcinoma of the lung. (1996) (0)
6563 POSTER High-dose 130-nanometer albumin-bound paclitaxel in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (2007) (0)
3109 nab-Paclitaxel (nab-P) plus carboplatin (C) as first-line treatment in patients with advanced non-small cell lung cancer (NSCLC): Clinical outcomes by treatment cycle (2015) (0)
P3.08-004 Phase I/II Trial of Nab-Paclitaxel or Paclitaxel Plus Carboplatin with Concurrent Radiation for Inoperable Stage IIIA/B NSCLC (2017) (0)
Low Risk of Hyperprogression with First-Line Chemoimmunotherapy for Advanced Non-Small Cell Lung Cancer: Pooled Analysis of 7 Clinical Trials (2023) (0)
Tumor dynamic model-based decision support for Phase Ib/II combination studies: A retrospective assessment based on resampling of the Phase III study IMpower150. (2023) (0)
Safety and tolerability of concurrent Nab-P (Nab-P) and Carbo (Carbo) with thoracic radiotherapy (RT) followed by consolidative Nab-P and Carbo in patients with stage IIIA/B non-small cell lung cancer (NSCLC). (2016) (0)
Outcomes for the elderly (≥70 years) from a three-arm phase III trial of gemcitabine in combination with carboplatin (GC) or paclitaxel (GP) versus paclitaxel plus carboplatin (PC) for advanced non-small cell lung cancer (NSCLC). (2009) (0)
Summary of EGFR-Biomarker data from the randomized, controlled phase 3 trial SQUIRE on adding Necitumumab to first-line Gemcitabine-Cisplatin (GC) for squamous Non-Small Cell Lung Cancer (sqNSCLC). (2017) (0)
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer (2017) (0)
Reply: Ongoing under-reporting of clinically relevant safety data in phase II studies of tyrosine kinase inhibitors (2010) (0)
Real-world progression-free survival of patients on anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) for ALK+ non-small cell lung cancer (NSCLC). (2018) (0)
Abstract 1744: A phase Ib study of bavituximab plus carboplatin and pemetrexed in chemotherapy naive stage IV non-squamous non-small cell lung cancer (2012) (0)
Final efficacy and safety results of ECOG Performance Status (PS) subgroup analyses from the SQUIRE phase III study (2015) (0)
PS 01 . 08 ABOUND . PS 2 Interim Safety Results : nab-Paclitaxel / Carboplatin Followed by nab-Paclitaxel in NSCLC Patients with ECOG PS of 2 Topic : Medical Oncology (2016) (0)
Phase I trial of escalating doses of ABI-007 (nanoparticle albumin-bound paclitaxel) and gemcitabine in patients (pts) with thoracic malignancies (2007) (0)
Induction Chemotherapy using Carboplatin(C), Irinotecan(I), and Paclitaxel(P) with Pegfilgrastim Followed by Concurrent Conformal Radiation Therapy (CRT) with Weekly Carboplatin/Paclitaxel and Daily Gefitinib (Iressa) Followed by Maintenance Gefitinib for Patients with Stage IIIA/B Non-Small Cell Lu (2005) (0)
Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). (2012) (0)
Quality of life (QoL) in patients (pts) with squamous (SCC) NSCLC treated with nab-paclitaxel with carboplatin (nab-P/C) induction therapy: Interim analysis of the phase III ABOUND.sqm study. (2016) (0)
Results of a Single-Institution Experience With Dose-Escalated Chemoradiation for Locally Advanced Unresectable Non-Small Cell Lung Cancer (2016) (0)
nab-paclitaxel (nab-P) + carboplatin (C) induction therapy in patients (Pts) with squamous (SCC) NSCLC: Interim quality of life (QoL) outcomes from the phase 3 ABOUND.sqm study (2016) (0)
O-267 Combined modality trials of the cancer and leukemia group B (CALGB): Analysis of factors influencing survival and toxicity (2003) (0)
Tumor burden (TB) and treatment exposure (TE) in patients (pts) with malignant pleural mesothelioma (MPM) receiving nintedanib (N)/placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in phase II of the LUME-Meso study. (2018) (0)
Adverse Overall Survival Impact of PD-L1 Positivity in Patients With KRAS G12C Mutation Is Abolished by the Immunotherapy. (2021) (0)
Gender disparities in hormone positive lung cancer. (2020) (0)
Atezolizumab in first-line treatment of metastatic nonsquamous non-small cell lung cancer in the real-world setting. (2021) (0)
P2.03b-035 EGFR FISH as Potential Predictor of Necitumumab Benefit with Chemotherapy in Squamous NSCLC: Subgroup Analyses from SQUIRE: Topic: Biomarkers (2017) (0)
PD-098 Initial results of pre-operative pulmonary function testing in patients with stage I–II Non-Small Cell Lung Cancer (NSCLC) treated with neoadjuvant chemotherapy with gem citabine-containing regimens (2005) (0)
The occurrence of grade 4 adverse events and survival outcomes in patients with nonsquamous non-small cell lung cancer receiving bevacizumab with chemotherapy in the phase III PointBreak and AVAiL studies. (2013) (0)
Fibroblastic growth factor pathway. (2009) (0)
72P Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET+ colorectal carcinoma as a unique molecular subset of CRC (2022) (0)
P-617 Evaluating the impact of neoadjuvant chemotherapy and surgeryon quality of life (QL) in patients with early stage NSCLC: A prospective analysis of the GINEST project (2005) (0)
O-310 Induction and concurrent chemotherapy with dose-escalated thoracic conformal radiation therapy (TCRT) in unresectable stage III A/B non-small cell lung cancer (NSCLC): A phase I trial (2003) (0)
Poziotinib in Treatment-Naïve Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-label Phase 2 Trial (Cohort 4). (2023) (0)
Defining high-quality NSCLC care at U.S. cancer centers. (2020) (0)
Commentary (Stinchcombe et al): Perspectives on Salvage Therapy for Non–Small-Cell Lung Cancer (2005) (0)
COVID-19 Outcomes in Stage IV Cancer Patients Receiving Immune Checkpoint Inhibitors (2022) (0)
1618PDOverall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM) (2017) (0)
Erratum: Combined modality therapy for stage III non-small cell lung cancer (Oncologist (2006), 11 (809-823)) (2006) (0)
Paraffin-based molecular diagnosis of lung cancer reproduces morphologic and molecular subtypes of lung cancer (2016) (0)
78 – Cancer du poumon (2011) (0)
483TiP A Phase (Ph) III clinical program: 1L atezolizumab (atezo) plus chemotherapy (chemo) in chemo-naive advanced NSCLC (2016) (0)
Abstract 4894: The HSP90 inhibitor ganetespib potentiates effect of ionizing radiation in human non-small cell lung cancer (2014) (0)
Highlights in NSCLC From the 2012 American Society of Clinical Oncology Annual Meeting. (2012) (0)
Small cell lung cancer (2011) (0)
MB or Not MB : The Current Question in Staging Non-small Cell Lung Cancer * (0)
A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer (2023) (0)
Carboplatin/paclitaxel (C/P) or carboplatin/vinorelbine (C/V) followed by accelerated hyperfractionated conformal radiation therapy (AHCRT): A phase I dose esclation trial from the Carolina conformal therapy consortium (2000) (0)
Comment on: High-dose conformal radiotherapy for treatment of stage III A/B non-small-cell lung cancer: Technical issues and results of a phase I/II trial. Authors' reply (2003) (0)
2002 Highlights From: 14th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics; Frankfurt, Germany November 19–22, 2002 (2003) (0)
Population pharmacokinetics (Pop PK) of MYL-1402O (a proposed biosimilar to bevacizumab) and reference product (Avastin) in patients with nonsquamous non-small cell lung cancer (nsNSCLC). (2021) (0)
Phase II clinical trial of atezolizumab (A) in advanced non-small cell lung cancer (NSCLC) patients (pts) previously treated with PD1-directed therapy. (2017) (0)
ALK-targeted therapy in NSCLC: likely to be of benefit but not quite ready for prime time. (2011) (0)
Response to Letter to the Editor. (2021) (0)
Comparison of circulating tumor DNA (ctDNA) sequencing and tumor-based genotyping for the detection of EGFR mutations in non-small cell lung cancer (NSCLC). (2017) (0)
DIAGNOSIS LUNG Treatment of Stage IV Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (2013) (0)
Title: Characterization of KRAS Mutation Subtypes in Non-Small Cell Lung Cancer (2021) (0)
Molecular markers distinguish patients at differential risk of brain metastases in lung cancer by immunohistochemistry (2008) (0)
Preliminary Results of a Phase 1b Study of Bavituximab (B) Plus Carboplatin (C) and Pemetrexed (P) in Chemotherapy-Naïve Stage IIIb/IV Nonsquamous NSCLC (2014) (0)
Therapeutic advances in non-small cell lung cancer: Highlights from the annual clinical cancer conferences (2011) (0)
Highlights in NSCLC from the 2014 ASCO meeting. (2014) (0)
Abstract #5460: Erlotinib in African Americans with lung cancer: a prospective, clinical, molecular, pharmacokinetic and pharmacogenetic characterization (2009) (0)
P2.03a-040 Safety and Efficacy of Nab-Paclitaxel for 2nd Line Treatment of Elderly Patients with Stage IV Non-Small Cell Lung Cancer: Topic: Clinical Trials (2017) (0)
B-F1RST: Assessment of novel blood-based biomarkers in patients with first-line advanced or metastatic NSCLC receiving atezolizumab monotherapy. (2017) (0)
Feasibility of adjuvant carboplatin/docetaxel (C/D) in patients (pts) resected stage I-IIIB non-small cell lung cancer (NSCLC): Preliminary report of a phase II trial (2007) (0)
Perspectives on salvage therapy for non-small-cell lung cancer: Commentary (2005) (0)
Oral Scientific SessionsHeart Dosimetric Analysis of Three Types of Cardiac Toxicity in Patients Treated on Dose-Escalation Trials for Stage III Non–small Cell Lung Cancer (2017) (0)
The many controversies of stage IIIA/IIIB lung cancer. (2010) (0)
Preliminary results of a phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology (NSCLC-NS) with disease progression after a bevacizumab (bev) containing therapy. (2014) (0)
The impact of COVID-19 infection on immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors. (2022) (0)
11 – Endocrine Neoplasia (2010) (0)
nab‐Paclitaxel + carboplatin (nab‐P/C) in advanced non‐small cell lung cancer (NSCLC): outcomes in elderly patients (pts) with squamous (SCC) histology: 216PD (2016) (0)
Clinical Outcomes of patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with nab-paclitaxel + carboplatin (nab-P/C) and solvent-based paclitaxel + carboplatin (sb-P/C) stratified by age and renal function: a retrospective analysis of a phase III trial. (2015) (0)
PD.01.01 Acquired EGFR Resistant Mutations and Co-mutations in Tumors Of Non-small Cell Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors (TKI) (2023) (0)
A Randomized Phase II Trial of First-Line Treatment with Gemcitabine, Erlotinib, or Gemcitabine and Erlotinib in Elderly Patients (Age (cid:1) 70 Years) with Stage IIIB/IV Non-small Cell Lung Cancer (2011) (0)
Vascular endothelial growth factor trap in non-small cell lung cancer. Discussion (2007) (0)
Rate of Lobar Collapse and/or Urgent Thoracic RT following Initial Chemotherapy for Advanced Non-small Cell Carcinoma (NSCLC): Implications for Selecting Patients for Early Intervention with Thoracic RT (2010) (0)
Preliminary results of a phase I trial of sorafenib combined with cisplatin/etoposide (CE) or carboplatin/pemetrexed (CbP) in solid tumor patients (pts). (2009) (0)
MA13.05 Nab-Paclitaxel Maintenance in Squamous Non-Small Cell Lung Cancer (NSCLC): Updated Results of the Phase III ABOUND.sqm Study (2019) (0)
Enrichment of Met Amplification and Kras Mutations in Non-Small Cell Lung Carcinoma (NSCLC) Brain Metastases (2014) (0)
A phase II trial of weekly 1-hour paclitaxel in stage IV melanoma (2005) (0)
Acceptable Safety of Bevacizumab Therapy in Patients with Brain Metastases as a Result of Non—Small-Cell Lung Cancer (2008) (0)
Abstract 2164: Lung adenocarcinoma subtypes have unique gene mutations (EGFR, TP53), DNA copy number alterations (3q26, 16p13), and patient smoking histories (2010) (0)
Immunohistochemical-based diagnosis of lung adenocarcinoma subtypes reproduces the results of gene expression profiling. (2011) (0)
Respiratory 2020: Oral Poziotinib shows clinical activity and durable response in previously treated EGFR exon 20 NSCLC patients –a phase 2 study- Mark A Socinski, Spectrum Pharmaceuticals Inc. (2020) (0)
Guidance for clinicians and patients with non-small cell lung cancer in the time of precision medicine (2023) (0)
P-796 A randomized phase II trial of pemetrexed (P) plus cisplatin (cis) or carboplatin (carbo) in extensive stage small cell lung cancer (ES-SCLC) (2005) (0)
Prescribing preferences (PPrefs) of US-based medical oncologists (MOs) for 1st salvage therapy (Tx) after response to 1st-line crizotinib (CRZ) in patients with anaplastic lymphoma kinase (ALK) positive non-small cell lung cancer (NSCLC). (2015) (0)
A Framework for Defining High-Quality Care for Patients with NSCLC (2021) (0)
Practice Guidelines ( 2 nd Edition ) Stage IV : ACCP Evidence-Based Clinical Treatment of Non-small Cell Lung Cancer (2007) (0)
Reducing preventable ED visits in patients with advanced NSCLC: Collective insights from three cancer centers. (2022) (0)
Integration of Biological Therapies in Locally Advanced Non-Small-Cell Lung Cancer (2006) (0)
Clinical Cancer esearch ing , Diagnosis , Prognosis g Squamous Cell Carcinoma mRNA Expression Subtypes Reproducible , Clinically Important , and Correspond R ormal Cell Types (2010) (0)
Specific Anti-Influenza Antibody Synthesis and Aging: In Vitro Effects of Thymosin (1986) (0)
Abstract 4682: Sunitinib (SU) in advanced NSCLC: Correlation of circulating biomarkers with clinical outcome (2010) (0)
PPD4-2-6: Feasibility of Adjuvant carboplatin/docetaxel (C/D) in patients (pts) resected stage I-IIIB non-small cell lung cancer (NSCLS): Preliminary report of a phase II trial (2007) (0)
Is there a genomic fingerprint of Radon (Rn)-induced lung cancer (LC)? Comparison of genomic alterations in LC specimens from high and low Rn zones. (2020) (0)
Seminars in Oncology: Introduction (2005) (0)
What constitutes high-quality NSCLC care? Overarching quality considerations for improving NSCLC care at US cancer centers. (2020) (0)
How I treat stage IV non-small cell lung cancer in the absence of any actionable oncogenic driver. (2017) (0)
Interprofessional care team practices and perspectives on immuno-oncology (IO) therapies for metastatic non-small cell lung cancer (mNSCLC): Insights from a nationwide survey. (2021) (0)
1172P High activity of poziotinib in G778_P780dup HER2 exon 20 insertion mutations in non-small cell lung cancer (NSCLC) (2022) (0)
Phase I/II study of rilotumumab (R) and erlotinib (E) in previously treated patients (pts) with metastatic NSCLC. (2015) (0)
Abstract A43: EGFR-targeted therapy in African Americans with advanced non-small cell lung cancer: A prospective clinical, pharmacogenetic, and pharmacokinetic study. (2012) (0)
Raising the level of cancer care: Feasibility and reported benefit of a virtual tumor board. (2022) (0)
Pemetrexed (akimta) in small cell lung cancer (2005) (0)
Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM). (2018) (0)
Association of high circulating neuregulin-1 with clinical benefit in EGFR wild-type NSCLC patients treated with rilotumumab and erlotinib. (2016) (0)
Acquired EGFR-resistant mutations in non–small cell lung cancer (NSCLC). (2022) (0)
PS01.08: ABOUND.PS2 Interim Safety Results: nab‐Paclitaxel/Carboplatin Followed by nab‐Paclitaxel in NSCLC Patients with ECOG PS of 2: Topic: Medical Oncology (2016) (0)
Oral Poziotinib shows clinical activity and durable response in previously treated EGFR exon 20 NSCLC patients Ã¢ÂÂa phase 2 study (2021) (0)
OA23.02 Efficacy and Safety of Necitumumab Continuation Monotherapy in Patients with EGFR-Expressing Tumors in SQUIRE, a Phase 3 Study (2017) (0)
MA06.10 A Pooled Analysis Comparing the Outcomes of Elderly to Younger Patients on NCTN Trials of Concurrent CCRT for Stage 3 NSCLC (2017) (0)
OA03.06 Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma: Topic: Medical Oncology (2017) (0)
43 Preoperative chemotherapy in early stage NSCLC: Parallel randomized phase II trials (2003) (0)
Enhancing clinician confidence on the therapeutic management of non-small cell lung cancer (NSCLC) through continuing medical education (CME). (2017) (0)
Platinum-based Adjuvant Chemotherapy for Resected Non-Small-Cell Lung Cancer: A New Standard of Care (2007) (0)
In response to Drs. Senan and Lagerwaard (2003) (0)
How Do I Treat a Patient with Extensive-Stage Small-Cell Lung Cancer? (2011) (0)
Should Bevacizumab Be Added to Non–Small-Cell Lung Cancer Therapy? (2007) (0)
Defining the Appropriate Place for Positron Emission Tomography Imaging in the Staging of Patients With Suspected Lung Cancer (2017) (0)
P22.02 Combined Use of CYFRA 21-1, CA125 and CRP Predicts Survival of Metastatic NSCLC Patients With Stable Disease (2021) (0)
Highlights in NSCLC from the American Society of Clinical Oncology Meeting, June 3-7, 2011, Chicago, Illinois, USA. (2011) (0)
P-687 Baseline hemoglobin as a prognostic factor of survival in patients with stage III non-small cell lung cancer (2003) (0)
Results from intermittent and continuous dosing schedules with sunitinib (SU) in previously treated, advanced non–small-cell lung cancer (NSCLC) (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Mark A. Socinski?

Mark A. Socinski is affiliated with the following schools:

McGill University
University of Alberta
Stanford University
University of Chicago
University of Las Palmas de Gran Canaria
University of Pittsburgh
University of North Carolina at Chapel Hill
University of Turin
Duke University
University of Utah
University of Western Australia
University of Pennsylvania

Mark A. Socinski's Academic­Influence.com Rankings